Bullet Biotechnology Inc MENU ABOUT US Who We Are Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers. Our pipeline has recently expanded and now includes two clinical-stage products with common regulatory and development strategies. Our cutting-edge scientific approach is focused on targets that are uniquely expressed within cancer cells, resulting in highly targeted new therapies. We also apply a variety of therapeutic strategies to address different medical challenges - from antibodies and antibody-drug conjugates (ADCs) to small molecules and chimeric antigen receptor T-cells (CAR-T). By leveraging our strong scientific and development skills, as well as academic collaborations, we are working to rapidly advance our two clinical-stage pipeline products, cirmtuzumab and TK216. Both cirmtuzumab and TK216 are being developed for various tumor types, including some of the most devastating and underserved forms of cancer. PARTNERSHIP OPPORTUNITIES Send Me News Updates by Email BACK TO HOME Contact © 2016 Oncternal Therapeutics. All rights reserved. Website by Centrifuge Media Lab.